Amir Abdallah1, Jonathan L Chang2, Cumara B O'Carroll3, Abdu Musubire4, Felicia C Chow5, Anthony L Wilson6, Mark J Siedner7. 1. Department of Medicine, Mbarara University of Science and Technology, Uganda. Electronic address: aamir@must.ac.ug. 2. Duke University School of Medicine, Durham, North Carolina. 3. Department of Neurology, Mayo Clinic, Scottsdale, Arizona. 4. Department of Medicine, Mulago National Referral Hospital, Uganda. 5. Department of Neurology and Division of Infectious Diseases, University of California, San Francisco, California. 6. Department of Medicine, Mbarara University of Science and Technology, Uganda. 7. Department of Medicine, Mbarara University of Science and Technology, Uganda; Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) infection is associated with worse outcomes after stroke, but this association is less well-described in sub-Saharan Africa (SSA). We reviewed literature on stroke among people living with HIV (PLWH) in SSA. METHODS: We systematically reviewed published literature for original clinical stroke studies conducted in SSA that included PLWH. We included studies that reported data on presenting characteristics, risk factors, and/or outcomes after stroke. RESULTS: Seventeen studies (N = 478) met inclusion criteria. At the time of stroke presentation, PLWH had a median age ranging from 32 to 43 years. Subjects had low CD4 counts (median CD4, 108-225 cells/µl), and most were antiretroviral therapy-naïve. Fever, seizures, and concurrent opportunistic infections were common at presentation. Ischemic stroke accounted for up to 96% of strokes, which were mostly located in the anterior circulation territory. In studies comparing PLWH with HIV-uninfected individuals, PLWH had more frequent coagulopathy, greater stroke severity, (72% versus 36% National Institutes of Health Stroke Scale >13, P = .02), longer hospital length of stay (30.5 versus <10 days), and a higher 30-day mortality rate (23% versus 10.5%, P = .007). CONCLUSION: Stroke in PLWH in SSA occurs at a young age, in those with advanced disease, and is associated with worse outcomes than in HIV-uninfected comparators. Stroke in young individuals in the region should prompt HIV testing, and ongoing efforts to promote early antiretroviral therapy initiation might also help decrease stroke incidence, morbidity, and mortality in the region.
BACKGROUND: Human immunodeficiency virus (HIV) infection is associated with worse outcomes after stroke, but this association is less well-described in sub-Saharan Africa (SSA). We reviewed literature on stroke among people living with HIV (PLWH) in SSA. METHODS: We systematically reviewed published literature for original clinical stroke studies conducted in SSA that included PLWH. We included studies that reported data on presenting characteristics, risk factors, and/or outcomes after stroke. RESULTS: Seventeen studies (N = 478) met inclusion criteria. At the time of stroke presentation, PLWH had a median age ranging from 32 to 43 years. Subjects had low CD4 counts (median CD4, 108-225 cells/µl), and most were antiretroviral therapy-naïve. Fever, seizures, and concurrent opportunistic infections were common at presentation. Ischemic stroke accounted for up to 96% of strokes, which were mostly located in the anterior circulation territory. In studies comparing PLWH with HIV-uninfected individuals, PLWH had more frequent coagulopathy, greater stroke severity, (72% versus 36% National Institutes of Health Stroke Scale >13, P = .02), longer hospital length of stay (30.5 versus <10 days), and a higher 30-day mortality rate (23% versus 10.5%, P = .007). CONCLUSION: Stroke in PLWH in SSA occurs at a young age, in those with advanced disease, and is associated with worse outcomes than in HIV-uninfected comparators. Stroke in young individuals in the region should prompt HIV testing, and ongoing efforts to promote early antiretroviral therapy initiation might also help decrease stroke incidence, morbidity, and mortality in the region.
Authors: Johanne M Garbusinski; Marianne A B van der Sande; Emmanuel J Bartholome; Michèle Dramaix; Alieu Gaye; Rosalind Coleman; Ousman A Nyan; Richard W Walker; Keith P W J McAdam; Gys E Walraven Journal: Stroke Date: 2005-06-09 Impact factor: 7.914
Authors: John W Cole; Amelia N Pinto; J Richard Hebel; David W Buchholz; Christopher J Earley; Constance J Johnson; Richard F Macko; Thomas R Price; Michael A Sloan; Barney J Stern; Robert J Wityk; Marcella A Wozniak; Steven J Kittner Journal: Stroke Date: 2003-12-18 Impact factor: 7.914
Authors: Amir Abdallah; Jonathan L Chang; Cumara B O'Carroll; Samson Okello; Sam Olum; Moses Acan; Abdirahim Abdi Aden; Felicia C Chow; Mark J Siedner Journal: Stroke Date: 2018-12 Impact factor: 7.914
Authors: Fred Stephen Sarfo; Ohene Opare-Sem; Martin Agyei; John Akassi; Dorcas Owusu; Mayowa Owolabi; Bruce Ovbiagele Journal: J Neurol Sci Date: 2018-09-20 Impact factor: 3.181
Authors: Craig Corbett; Naeem Brey; Richard D Pitcher; Suzanne O'Hagan; Tonya M Esterhuizen; Felicia C Chow; Eric H Decloedt Journal: Neurology Date: 2022-06-03 Impact factor: 11.800
Authors: Amir A Mbonde; Jonathan Chang; Abdu Musubire; Samson Okello; Adrian Kayanja; Moses Acan; Jacob Nkwanga; Andrew Katende; Felicia C Chow; Deanna Saylor; Cumara O'Carroll; Mark J Siedner Journal: J Stroke Cerebrovasc Dis Date: 2022-04-25 Impact factor: 2.677
Authors: Kaku So-Armah; Laura A Benjamin; Gerald S Bloomfield; Matthew J Feinstein; Priscilla Hsue; Benson Njuguna; Matthew S Freiberg Journal: Lancet HIV Date: 2020-04 Impact factor: 16.070
Authors: Mark J Siedner; Prossy Bibangambah; June-Ho Kim; Alexander Lankowski; Jonathan L Chang; Isabelle T Yang; Douglas S Kwon; Crystal M North; Virginia A Triant; Christopher Longenecker; Brian Ghoshhajra; Robert N Peck; Ruth N Sentongo; Rebecca Gilbert; Bernard Kakuhikire; Yap Boum; Jessica E Haberer; Jeffrey N Martin; Russell Tracy; Peter W Hunt; David R Bangsberg; Alexander C Tsai; Linda C Hemphill; Samson Okello Journal: J Am Heart Assoc Date: 2021-06-05 Impact factor: 6.106